Belgian Biotech Agomab Debuts on Nasdaq with a $200 Million IPO
Just weeks after announcing its plans for a U.S. listing, Belgium-based Agomab Therapeutics has gone public on Nasdaq, pricing its IPO at $16 per share to raise about $200 million. The stock is now trading under the ticker AGMB, putting the spotlight on fibrosis in what has been a billion-dollar week for biotech IPOs.
Agomab Therapeutics is developing therapies for immunological and inflammatory diseases where fibrosis drives long-term damage. At the IPO price, Agomab was valued at roughly $780 million (€660 million), underscoring the scale of investor interest in its fibrosis-focused approach, even before it has a product on the market.